Scinai Immunotherapeutics Ltd. (SCNI)

NCM – Real Time Price. Currency in USD

0.53

+0.02 (4.02%)

At close: May 12, 2026, 4:00 PM EDT

0.54

+0.01 (1.89%)

After-hours: May 12, 2026, 6:51 PM EDT

24.04.2026

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics Ltd – ADR (NASDAQ:SCNI) shares are surging Friday morning after the company announced fresh financing tied to a private placement and warrant exercise, helping refocus attention on its near-term funding runway. Here's what investors need to know.

24.04.2026

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Financing led by institutional life sciences investor, with participation from new and existing investors Capital expected to support expansion of CDMO platform and advancement of customer programs JERUSALEM, April 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics and the owner of Scinai Biopharma Services Ltd.

06.04.2026

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

JERUSALEM, April 6, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company developing inflammation and immunology therapeutics and operating a growing CDMO business, today announced the completion of a strategic corporate reorganization establishing a dedicated CDMO platform alongside a streamlined R&D organization.

01.04.2026

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025.

19.03.2026

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd.

16.03.2026

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days.

02.03.2026

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

JERUSALEM, March 2, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI);("Scinai" or the "Company"), today announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l.

Videos

No Data

There is no data to display

Press releases

24.04.2026

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

06.04.2026

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

01.04.2026

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

19.03.2026

Scinai Immunotherapeutics Ltd. (SCNI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Scinai Immunotherapeutics Ltd. (SCNI)

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Videos

No Data

Press releases

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Videos

No Data

Press releases

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Search stocks

Scinai Immunotherapeutics Ltd. (SCNI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Scinai Immunotherapeutics Ltd. (SCNI)

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Videos

No Data

Press releases

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Videos

No Data

Press releases

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026